Azmacort and Fosamax drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Azmacort (triamcinolone acetonide) and Fosamax (alendronate sodium). Common drug interactions include muscle spasms among females and back pain among males.
The phase IV clinical study analyzes what interactions people have when they take Azmacort and Fosamax. It is created by eHealthMe based on reports of 147 people who take the same drugs from the FDA, and is updated regularly.
What is Azmacort?
Azmacort has active ingredients of triamcinolone acetonide. It is often used in asthma. eHealthMe is studying from 3,612 Azmacort users. Check the latest studies of Azmacort.
What is Fosamax?
Fosamax has active ingredients of alendronate sodium. It is often used in osteoporosis. eHealthMe is studying from 105,452 Fosamax users. Check the latest studies of Fosamax.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
147 people who take Azmacort and Fosamax together, and have interactions are studied.
What are the common drug interactions of Azmacort and Fosamax, by gender? *
What are the common drug interactions of Azmacort and Fosamax, by age (0-1 to 60+)? *
What are the existing conditions these people have? *
* Approximation only. Some reports may have incomplete information.
Do you take Azmacort and Fosamax?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Azmacort and Fosamax:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Azmacort:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Fosamax:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Azmacort and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Fosamax and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
- Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
- Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
- Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
How the study uses the data?
The study uses data from the FDA. It is based on triamcinolone acetonide and alendronate sodium (the active ingredients of Azmacort and Fosamax, respectively), and Azmacort and Fosamax (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Ceftriaxone cause Reflux Oesophagitis? - 10 seconds ago
- Could Entyvio cause Birth Control? - 11 seconds ago
- Could Ceftriaxone cause Musculoskeletal Pain? - 11 seconds ago
- Could Melphalan Hydrochloride cause Diverticulitis? - 19 seconds ago
- Actemra and Joint Ankylosis for Men aged 50-59 - 20 seconds ago
- Could Melatonin cause Restlessness Aggravated? - 21 seconds ago
- Could Melatonin cause Malignant Neoplasm Progression? - 24 seconds ago
- Could Melatonin cause Hypothyroidism? - 27 seconds ago
- Could Pristiq cause Drug Ineffective? - 31 seconds ago
- Amlodipine and Cryptococcosis for Men aged 60+ - 32 seconds ago